Compare Meta Platforms Inc (META) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Recursion Pharmaceuticals Inc — how do they compare? Meta Platforms Inc trades at $647.7 (market cap $1.64T), while Recursion Pharmaceuticals Inc trades at $3.05 (market cap $1.53B). The key difference: Meta Platforms Inc is far larger — about 1071.9× Recursion Pharmaceuticals Inc's market cap, and Meta Platforms Inc pays a 0.33% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| META | RXRX | |
|---|---|---|
Market Cap | $1.64T | $1.53B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $6.79 |
52-Week Low | $525.72 | $2.84 |
Enterprise Value | $1.65T | $946.50M |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $647.42, up 0.22% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 23.49, net income margin of 32.84%, and consistent earnings beats. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, though it faces a youth addiction lawsuit in Massachusetts.
Outlook remains positive with analyst consensus at Buy (79.37%) and a $817.32 price target, supported by robust revenue growth and AI investments. Key risks include regulatory lawsuits and high capital expenditures. The stock presents a growth opportunity but requires monitoring of legal and competitive pressures.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
